CRISPR Therapeutics AG 2026年季度报告

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject tosuch filing requirements for the past 90 days.YES☒NO☐ Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required tosubmit such files).YES☒NO☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company,or emerging growth company. See definition of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growthcompany” in Rule 12b-2 of the Exchange Act. Throughout this Quarterly Report on Form 10-Q, the “Company,” “CRISPR,” “CRISPR Therapeutics,” “we,” “us,” and“our,” except where the context requires otherwise, refer to CRISPR Therapeutics AG and its consolidated subsidiaries; “ourboard of directors” refers to the board of directors of CRISPR Therapeutics AG; and we generally refer to CASGEVY® “CRISPR Therapeutics®“CTX310® ,” “CTX321™,” “CTX340™,” “CTX460™,” “CTX611™”and “SyNTase™”are trademarks and registeredtrademarks of CRISPR Therapeutics AG. CASGEVY®and the CASGEVY logo are registered trademarks of Vertex Pharmaceuticals Incorporated, and Vertex Pharmaceuticals Incorporated is the manufacturer and exclusive license holder of CASGEVY. All othertrademarks and registered trademarks contained in this Quarterly Report on Form 10-Q are the property of their respectiveowners. Solely for convenience, trademarks, service marks and trade names referred to in this Quarterly Report on Form 10-Q may appear without the ® or ™ symbols and any such omission is not intended to indicate waiver of any such rights.FORWARD-LOOKING STATEMENTS This Quarterly Report on Form 10-Q contains “forward-looking statements” that involve substantial risks and uncertainties.All statements, other than statements of historical facts, contained in this Quarterly Report on Form 10-Q are forward-lookingstatements. These statements are often identified by the use of words such as “anticipate,” “believe,” “continue,” “could,”“estimate,” “expect,” “intend,” “may,” “plan,” “predict,” “project,” “potential,” “will,” “would” or the negative or plural of thesewords or similar expressions or variations, although not all forward-looking statements contain these identifying words. Forward- •our strategic plans to develop and, if approved, subsequently commercialize any product candidates we may develop,including plans and expectations for the commercialization of, and anticipated benefits of, CASGEVY, including plansfor patient access to CASGEVY; •the safety, efficacy and clinical progress of various clinical programs, including those for CASGEVY, zugocabtagenegeleucel, CTX310 and CTX611; •the status of clinical trials, including development timelines and discussions with regulatory authorities related toproduct candidates under development by us and us and our collaborators; •the results of preclinical studies and clinical trials, including ongoing clinical trials and any planned clinical trials, andresearch and development programs; •the actual or potential benefits of regulatory designations, such as orphan drug, fast track and regenerative medicineadvanced therapy in the United States or such European equivalents; •our ability to advance product candidates into, and successfully complete, clinical trials; •the size and growth potential of the markets for our product candidates and our ability to serve those markets, includingour estimates regarding the addressable patient population and potential market opportunity for our current and futureproduct candidates; •the rate and degree of market acceptance of our product candidates and the success of competing therapies that are orbecome available; •our internal manufacturing capabilities and operation of our cell therapy manufacturing facility; •our intellectual property coverage and positions, including those of our licensors and third parties as well as the statusand potential outcome of proceedings involving any such intellectual property; •the expected benefits of our collaborations; •our strategy, goals, and anticipated financial performance; •our ability to service or pay down existing or future debt obligations; •our anticipated expenses, ability to obtain funding for our operations and the sufficiency of our cash resources; •the therapeutic value, development, and commercial potential of gene editing technologies and therapies, includingCRISPR/Cas9 and SyNTase, as well as other technologies we develop and use, including delivery and sm